RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial

被引：0

作者：

Johnson, M. L. ^{[1
,2
]}

Langdon, R. ^{[3
]}

Ellison, D. ^{[4
]}

Spira, A. ^{[5
]}

Amin, H. ^{[6
]}

Castine, M. ^{[7
]}

Daniel, D. ^{[8
]}

Larson, T. ^{[9
]}

Sohoni, S. ^{[10
]}

Chen, Y. C. ^{[10
]}

Hayes, J. ^{[10
]}

Yang, L. ^{[10
]}

Masciari, S. ^{[11
]}

Wang, X. ^{[10
]}

Toya, S. ^{[12
]}

机构：

[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[2] Nebraska Canc Specialists, Omaha, NE USA

[3] Nebraska Canc Specialists, Omaha, NE USA

[4] Charleston Oncol PA, Charleston, SC USA

[5] USOR, Virginia Canc Specialists, Fairfax, VA USA

[6] Boca Raton Clin Res Assoc Inc, Plantation, FL USA

[7] Hematol Oncol Clin, Baton Rouge, LA USA

[8] Sarah Cannon Res Inst Tennessee Oncol, Chattanooga, TN USA

[9] Minnesota Oncol Hematol PA, Minneapolis, MN USA

[10] Revolut Med, Redwood City, CA USA

[11] Sanofi, Cambridge, MA USA

[12] GenHarp Clin Solut LLC, Evergreen Pk, IL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

SHP2; RAS; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.02-11

引用

页码：S454 / S455

页数：2

共 5 条

[1] Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
Falchook, G.
Li, B. T.
Marrone, K. A.
Bestvina, C. M.
Langer, C. J.
Krauss, J. C.
Strickler, J. H.
Meloni, A.
Dai, T.
Varrieur, T.
Hong, D. S.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S8 - S8
[2] A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC
Malhotra, J.
Li, X.
Palmer, J.
Synold, T. W.
Mohanty, A.
Singhal, S.
Kulkarni, P.
Salgia, R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S659 - S660
[3] HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
Ho, Cassandra S. L.
Tuens, Alicia, I
Schildhaus, Hans-Ulrich
Wiesweg, Marcel
Gruener, Barbara M.
Hegedus, Balazs
Schuler, Martin
Schramm, Alexander
Oeck, Sebastian
EUROPEAN JOURNAL OF CANCER, 2021, 159 : 16 - 23
[4] SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation
Lee, C.
Pavlakis, N.
Zhou, D. D. -X.
Brown, C.
Hughes, B. G. M.
Yip, S.
Bray, V. J.
Daley, F. T.
Roberts-Thomson, R.
Cummins, M. M.
John, T.
Solomon, B. J.
Mitchell, P.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S362
[5] CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer
Prahallad, Anirudh
Weiss, Andreas
Voshol, Hans
Kerr, Grainne
Sprouffske, Kathleen
Yuan, Tina
Ruddy, David
Meistertzheim, Morgane
Kazic-Legueux, Malika
Kottarathil, Tina
Piquet, Michelle
Cao, Yichen
Martinuzzi-Duboc, Laetitia
Buhles, Alexandra
Adler, Flavia
Mannino, Salvatore
Tordella, Luca
Sansregret, Laurent
Maira, Sauveur-Michel
Graus Porta, Diana
Fedele, Carmine
Brachmann, Saskia M.
CANCER RESEARCH, 2023, 83 (24) : 4130 - 4141

← 1 →